Home・Akcijų sąrašas・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Atidarymo kaina

14.53 3.42

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

14.04

Max

14.68

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-4.3M -18M
Pelnas, tenkantis vienai akcijai	-0.19
Darbuotojai	37
EBITDA	-5.3M -17M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+109.37% upside

Dividendai
By Acuity
Kitas uždarbis	2026-11-03

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	130M 1.3B
Ankstesnė atidarymo kaina	11.11
Ankstesnė uždarymo kaina	14.53

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-24 23:56; UTC

Community Healthcare Trust Inc. shares are lower in after-market hours amid broader market caution related to geopolitical tensions and new U.S.-Iran sanctions.

2026-08-24 23:56; UTC

Ares Capital Corp shares are trading roughly flat in after-hours. The stock remains above its 20-day moving average amid broader market caution.

2026-08-24 23:56; UTC

Social Media

DICK'S Sporting Goods shares are higher in after-market trading as investors await earnings announcement tomorrow, despite earlier pulling back from a session high.

2026-08-24 23:56; UTC

Dillard's Inc shares are lower in after-market hours amid cautious market sentiment influenced by geopolitical tensions and economic concerns.

2026-08-24 23:56; UTC

Axon Enterprise Inc. shares advanced in after-market trading, following a higher close on Monday amid heightened market caution regarding U.S.-Iran relations and new sanctions.

2026-08-24 23:56; UTC

Dycom Industries Inc shares are higher in after-market trading, reflecting a positive shift after five consecutive sessions of lower closes.

2026-08-24 23:56; UTC

Vontier Corp shares traded roughly flat in after-market hours, remaining within a routine range since Monday's close.

2026-08-24 23:56; UTC

Resmed Inc. shares are lower in after-market hours amid weak trading sentiment. No specific company news was identified to explain the decline.

2026-08-24 23:56; UTC

Morgan Stanley shares are higher in after-market trading following Monday's close. The stock reached a session high earlier in the session.

2026-08-24 23:56; UTC

Kanzhun Ltd shares increased in after-market trading, despite no specific news. Investor caution remains amid concerns over U.S.-Iran relations and economic implications.

2026-08-24 23:56; UTC

Gogo Inc. shares are lower in after-market trading, continuing a decline since Monday amid broader market caution over geopolitical tensions and oil supply concerns.

2026-08-24 23:56; UTC

Textron Inc shares are lower in after-market hours amid broader market caution linked to U.S.-Iran tensions and new sanctions affecting oil supply.

2026-08-24 23:56; UTC

Dominion Energy shares are higher in after-market trading, reflecting a modest increase since Monday's close. The stock remains below its 20-day moving average.

2026-08-24 23:56; UTC

Chipotle Mexican Grill Inc shares are lower in after-market hours amid broader market caution linked to geopolitical tensions and new sanctions affecting economic conditions.

2026-08-24 23:56; UTC

Mid-America Apartment Communities shares are lower in after-market hours, reflecting notable volatility amid cautious broader market sentiment over geopolitical tensions.

2026-08-24 23:56; UTC

Kulicke and Soffa Industries shares are higher in after-market hours, reflecting positive movement since Monday's close amid broader market caution.

2026-08-24 23:56; UTC

Watsco Inc. shares are lower in after-market trading, continuing a trend of four consecutive daily declines and remaining below the 20-day moving average.

2026-08-24 23:56; UTC

NRG Energy Inc shares are trading higher in after-market hours. Broader market dynamics may be influencing investor sentiment amid concerns over U.S.-Iran relations.

2026-08-24 23:56; UTC

Markel Group Inc. shares declined in after-market trading amid broader market caution related to geopolitical tensions and new sanctions, now 2.90% below its 20-day moving average.

2026-08-24 23:56; UTC

Match Group Inc shares are lower in after-market trading. Broader market caution persists amid concerns over U.S.-Iran relations and oil supply disruptions.

2026-08-24 23:56; UTC

General Mills Inc shares are lower in after-market hours, reflecting volatility amid broader market caution over U.S.-Iran relations and potential oil supply disruptions.

2026-08-24 23:56; UTC

Correlated Moves

The US 30Y Treasury Bond Index is trading lower amid market caution over U.S.-Iran tensions and new sanctions impacting oil supply concerns.

2026-08-24 23:52; UTC

APA Corp. shares are trading higher in after-market hours, reflecting a routine move. The stock has seen notable gains over the past month.

2026-08-24 23:51; UTC

Hyatt Hotels Corp shares are lower in after-market hours, following a notable dip earlier amid volatility in U.S. Treasury yields and inflation concerns.

2026-08-24 23:51; UTC

HP Inc. shares are lower in after-market hours, reversing a recent trend of higher daily closes despite an earlier rebound from session lows.

2026-08-24 23:51; UTC

Shares of Science Applications International Corp. are lower in after-market trading, declining from earlier session peaks amid no specific news or developments.

2026-08-24 23:51; UTC

ArcBest Corp shares are lower in after-market hours, continuing weak trading conditions. The stock remains below its 20-day moving average and near recent lows.

2026-08-24 23:51; UTC

PENN Entertainment Inc shares are higher in after-market trading, despite remaining near the lower end of their one-month range and below the 20-day moving average.

2026-08-24 23:51; UTC

Correlated Moves

Social Media

SPDR Gold Shares are higher in after-market hours, continuing a recent upward trend amid mixed global equity indices and rising silver prices.

2026-08-24 23:51; UTC

Deluxe Corp's shares are lower in after-market trading, reflecting weaker performance below its 20-day moving average and near the lower end of its one-month range.

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

109.37% į viršų

12 mėnesių prognozė

Vidutinis 29.5 USD 109.37%

Aukščiausias 33 USD

Žemiausias 27 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Corvus Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.